Skip to main content

Table 2 Factors associated with long-term outcomes pancreatic cancer derived from univariate analysis and multivariate analysis (n = 1,082)

From: Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients

 

Hazard ratio

95% CI

P-value

Univariate analysis

   

  Age < 65 years old

0.80

0.67 ‒ 0.94

0.0072

  Female

0.95

0.82 ‒ 1.11

0.5648

  Surgery (vs. Chemotherapy)

0.31

0.24 ‒ 0.40

<0.0001

  Surgery (vs. BSC)

0.11

0.08 ‒ 0.14

<0.0001

  Chemotherapy (vs. BSC)

0.34

0.29 ‒ 0.40

<0.0001

  Tumor Location (Head)

0.77

0.66 ‒ 0.91

0.0015

  Group B (2006–2010)

0.81

0.69 ‒ 0.94

0.0063

  Stage I‒III

0.32

0.25 ‒ 0.40

<0.0001

Multivariate analysis

   

  Age < 65 years old

0.94

0.79 ‒ 1.11

0.4581

  Surgery (vs. Chemotherapy)

0.43

0.33 ‒ 0.56

<0.0001

  Surgery (vs. BSC)

0.13

0.10 ‒ 0.18

<0.0001

  Chemotherapy (vs. BSC)

0.31

0.26 ‒ 0.37

<0.0001

  Tumor Location (Head)

0.83

0.71 ‒ 0.98

0.0294

  Group B (2006–2010)

0.91

0.78 ‒ 1.06

0.2357

  Stage I‒III

0.46

0.36 ‒ 0.59

<0.0001

  1. BSC, best supportive care.